Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
作者信息
Otrock Zaher K, Mahfouz Rami A, Fahed Zahera, Farhat Fadi S, Ziade Azzam, Nasr Fadi, Kassem Nader, Abboud Miguel R
出版信息
Int J Hematol. 2012 Oct;96(4):521-4. doi: 10.1007/s12185-012-1168-9. Epub 2012 Sep 9.
PMID:22961257
Abstract
摘要
Zotero 插件